Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abiomed Inc (NQ: ABMD )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abiomed Inc

< Previous 1 2 3 4 5 Next >
What 4 Analyst Ratings Have To Say About Abiomed
Abiomed (NASDAQ:ABMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Recap: Abiomed Q3 Earnings
  Abiomed (NASDAQ:ABMD) reported its Q3 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 3, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter. 
Via Benzinga
First Patient in Japan Treated with Impella 5.5 with SmartAssist
From Abiomed, Inc.
Via Business Wire
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. 
Via InvestorPlace
Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French
From Abiomed, Inc.
Via Business Wire
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Abiomed's Return On Capital Employed Insights
According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million. 
Via Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year
From Abiomed, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Ominous Death Cross Forms On Abiomed's Chart
If history is any guide, there may be trouble ahead for shares of Abiomed (NASDAQ:ABMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology
From Abiomed, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Inari Medical (NASDAQ:NARI) stock... 
Via Benzinga
Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study
From Abiomed, Inc.
Via Business Wire
Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Abiomed, Inc.
Via Business Wire
Abiomed to Present at Upcoming Investor Conferences
From Abiomed, Inc.
Via Business Wire
Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
From Abiomed, Inc.
Via Business Wire
Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
From Abiomed, Inc.
Via Business Wire
TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
From Abiomed, Inc.
Via Business Wire
ABIOMED, inc (ABMD) Q2 2022 Earnings Call Transcript
ABMD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
From Abiomed, Inc.
Via Business Wire
Abiomed's Earnings Outlook
Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
From Abiomed, Inc.
Via Business Wire
Smallest Heart Pump From Abiomed Gets FDA Breakthrough Device Tag
The FDA has granted breakthrough device designation to Abiomed Inc's (NASDAQ: ABMD) Impella ECP expandable percutaneous heart pump. Abiomed designed the... 
Via Benzinga
Exposures Product Safety
FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump
From Abiomed
Via Business Wire
ABIOMED, inc (ABMD) Q1 2022 Earnings Call Transcript
ABMD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.